| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TCL1B |
| Uniprot No | O95988 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-128aa |
| 氨基酸序列 | MASEASVRLG VPPGRLWIQR PGIYEDEEGR TWVTVVVRFN PSRREWARAS QGSRYEPSIT VHLWQMAVHT RELLSSGQMP FSQLPAVWQL YPGRKYRAAD SSFWEIADHG QIDSMEQLVL TYQPERKD |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TCL1B重组蛋白的3篇参考文献的简要总结：
1. **文献名称**: "Structural and Functional Analysis of TCL1B Recombinant Protein in Leukemogenesis"
**作者**: Smith A, et al.
**摘要**: 本研究通过重组表达技术制备了TCL1B蛋白，解析了其三维结构，并发现其通过与AKT激酶相互作用促进细胞增殖，可能参与T细胞白血病的发生机制。
2. **文献名称**: "TCL1B Recombinant Protein Enhances B-Cell Lymphoma Cell Survival via NF-κB Pathway Activation"
**作者**: Zhang Y, et al.
**摘要**: 研究利用重组TCL1B蛋白进行体外实验，证明其通过激活NF-κB信号通路抑制B细胞淋巴瘤细胞凋亡，为TCL1家族蛋白的致癌机制提供了新证据。
3. **文献名称**: "Expression and Purification of Recombinant TCL1B for Antibody Development in Autoimmune Diseases"
**作者**: Lee JH, et al.
**摘要**: 开发了一种高效的大肠杆菌表达系统生产重组TCL1B蛋白，验证其抗原性并用于制备特异性抗体，为自身免疫疾病的诊断工具开发奠定基础。
注：以上文献信息为示例性概括，实际研究中请通过PubMed或Web of Science检索具体文献(关键词：TCL1B recombinant protein, TCL1 family, leukemia)。
**Background of TCL1B Recombinant Protein**
T-cell leukemia/lymphoma 1B (TCL1B) is a member of the TCL1 protein family, initially identified for its role in T-cell malignancies. The TCL1 gene family, including TCL1A and TCL1B, encodes small cytoplasmic proteins that form homodimers or heterodimers to regulate cellular processes. TCL1B shares structural and functional similarities with TCL1A, featuring a β-barrel fold that facilitates interactions with signaling molecules, notably Akt (protein kinase B). These interactions enhance Akt phosphorylation and activation, promoting cell survival, proliferation, and metabolic regulation—pathways often dysregulated in cancer.
TCL1B is implicated in oncogenesis, particularly in T-cell leukemias and lymphomas, where chromosomal translocations or dysregulated expression contribute to malignant transformation. Its overexpression has been observed in aggressive hematologic malignancies, suggesting a potential role as a biomarker or therapeutic target. Beyond cancer, TCL1B is expressed in immune cells and may influence lymphocyte development and function.
Recombinant TCL1B protein is produced using expression systems (e.g., *E. coli* or mammalian cells) to ensure proper folding and post-translational modifications. This engineered protein serves as a critical tool for studying TCL1B-Akt interactions, signaling cascades, and mechanisms underlying tumorigenesis. It also aids in developing targeted therapies, such as small-molecule inhibitors or antibodies, to disrupt oncogenic pathways.
Current research focuses on elucidating TCL1B's tissue-specific roles, its interplay with other oncoproteins, and its potential in diagnostics and immunotherapy. Challenges include understanding its regulation in non-malignant contexts and optimizing therapeutic strategies to mitigate off-target effects. Overall, TCL1B recombinant protein remains a vital resource for advancing both basic and translational cancer research.
×
